Tags

Type your tag names separated by a space and hit enter

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
Ann Rheum Dis. 2011 Jun; 70(6):905-8.AR

Abstract

This paper presents the second update of the Assessment in SpondyloArthritis international Society (ASAS) consensus statement on the use of anti-tumour necrosis factor (anti-TNF) agents in patients with axial spondyloarthritis (SpA). A major change from the previous recommendations is that patients fulfilling the ASAS axial SpA criteria, which also include patients fulfilling the modified New York criteria for ankylosing spondylitis, can be treated with anti-TNF agents. This makes an earlier start in the disease process possible. A second major change is the mandatory pretreatment before anti-TNF agents can be started. All patients should have tried a minimum of two non-steroidal anti-inflammatory drugs for a minimum of 4 weeks in total. This is significantly shorter than the previous requirement of 3 months. As previously, patients with axial symptoms require no further pretreatment. Patients with symptomatic peripheral symptoms should normally have had an adequate therapeutic trial of a disease-modifying antirheumatic drug, preferably sulfasalazine. Sulfasalazine is no longer mandatory in this group of patients. Finally, efficacy should be evaluated after at least 12 weeks. The remaining recommendations stayed largely unchanged.

Authors+Show Affiliations

Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. d.vanderheijde@kpnplanet.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Consensus Development Conference
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21540200

Citation

van der Heijde, Désirée, et al. "2010 Update of the International ASAS Recommendations for the Use of anti-TNF Agents in Patients With Axial Spondyloarthritis." Annals of the Rheumatic Diseases, vol. 70, no. 6, 2011, pp. 905-8.
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8.
van der Heijde, D., Sieper, J., Maksymowych, W. P., Dougados, M., Burgos-Vargas, R., Landewé, R., Rudwaleit, M., & Braun, J. (2011). 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 70(6), 905-8. https://doi.org/10.1136/ard.2011.151563
van der Heijde D, et al. 2010 Update of the International ASAS Recommendations for the Use of anti-TNF Agents in Patients With Axial Spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. PubMed PMID: 21540200.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. AU - van der Heijde,Désirée, AU - Sieper,Joachim, AU - Maksymowych,Walter P, AU - Dougados,Maxime, AU - Burgos-Vargas,Rubén, AU - Landewé,Robert, AU - Rudwaleit,Martin, AU - Braun,Jürgen, AU - ,, PY - 2011/5/5/entrez PY - 2011/5/5/pubmed PY - 2011/7/14/medline SP - 905 EP - 8 JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. VL - 70 IS - 6 N2 - This paper presents the second update of the Assessment in SpondyloArthritis international Society (ASAS) consensus statement on the use of anti-tumour necrosis factor (anti-TNF) agents in patients with axial spondyloarthritis (SpA). A major change from the previous recommendations is that patients fulfilling the ASAS axial SpA criteria, which also include patients fulfilling the modified New York criteria for ankylosing spondylitis, can be treated with anti-TNF agents. This makes an earlier start in the disease process possible. A second major change is the mandatory pretreatment before anti-TNF agents can be started. All patients should have tried a minimum of two non-steroidal anti-inflammatory drugs for a minimum of 4 weeks in total. This is significantly shorter than the previous requirement of 3 months. As previously, patients with axial symptoms require no further pretreatment. Patients with symptomatic peripheral symptoms should normally have had an adequate therapeutic trial of a disease-modifying antirheumatic drug, preferably sulfasalazine. Sulfasalazine is no longer mandatory in this group of patients. Finally, efficacy should be evaluated after at least 12 weeks. The remaining recommendations stayed largely unchanged. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/21540200/2010_Update_of_the_international_ASAS_recommendations_for_the_use_of_anti_TNF_agents_in_patients_with_axial_spondyloarthritis_ L2 - https://ard.bmj.com/cgi/pmidlookup?view=long&pmid=21540200 DB - PRIME DP - Unbound Medicine ER -